Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours

Bibliography

• ANDREASEN PA, KJOLLER L, CHRISTENSEN L, DUFFY MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. Cancer (1997) 72:1–22.
   PubMed Web of Science ®Google Scholar
• SCHMITT M, HARBECK N, THOMSSEN C et al.: Clinical impact of the plasminogen activator system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemostasis (1997) 78(1):285–296.
   PubMed Web of Science ®Google Scholar
• SCHMITT M, WILHELM 0, REUNING U et al.: The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis (2000) 14(2/3):114–132.
   Google Scholar
• ••Review on the uPA system in cancerinvasion and metastasis.
   Google Scholar
• SCHMITT M, JANICKE F, GRAEFF H: Tumor-associated proteases. Fibrizzaysis (1992) 6:3–26.
   Google Scholar
• REUNING U, MAGDOLEN V, WILHELM 0 etal.: Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Intl Oncology (1998) 13:893–906.
   Google Scholar
• •Review of the prognostic relevance for the urokinase system in different cancer types.
   Google Scholar
• HARBECK N, THOMSSEN C, BERGER U et al.: Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res. Treat. (1999) 54:147–157.
   PubMed Web of Science ®Google Scholar
• JANICKE E PRECHTL A, THOMSSEN C et al.: Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator inhibitor type 1.1 Natl. Cancer Inst. (2001) 93:913–920.
   Google Scholar
• ••Interim analyses on the significance of uPAand PAT-1 in cancer.
   Google Scholar
• SCHMALFELDT B, KUHN W REUNING U et al.: Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res. (1995) 55:3958–3963.
   Google Scholar
• NOACK F, SCHMITT M, BAUER J et al.: A new approach to phenotyping disseminated tumor cells: methodological advances and clinical implications. Int. Biol. Markers (2000) 15(1):100–104.
   PubMed Web of Science ®Google Scholar
• HEISS MM, ALLGAYER H, GRUETZNER KU et al.: Individual development and uPA-Receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nature Med. (1995) 1:1035–1039.
   PubMed Web of Science ®Google Scholar
• DUFFY MJ: Proteases as prognostic markers in cancer. Clin. Cancer Res. (1996) 2:613–618.
   PubMed Web of Science ®Google Scholar
• KOS J, LAH TT: Cysteine proteinases andtheir endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). Oncology Reports (1998) 5:1349–1361.
   PubMed Web of Science ®Google Scholar
• HARBECK N, ALT U, BERGER U et al.: Long-term follow-up confirms prognostic impact of PAI-1 and cathepsins D and L in primary breast cancer. Int. j Biol. Markers (2000) 15:79–83.
   PubMed Web of Science ®Google Scholar
• KUTE TE, GROHNDAHL-HANSEN J, SHAO SM, LONG R, RUSSELL G, BRUNNER N: Low cathepsin D and low plasminogen activator Type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res. Treat. (1998) 47:9–16.
   PubMed Web of Science ®Google Scholar
• THOMSSEN C, OPPELT P, JANICKE F et al.: Identification of low-risk node-negative breast cancer patients by tumor-biological factors PM-1 and cathepsin L. Anti-Cancer Res. (1998) 18:2173–2180.
   PubMed Web of Science ®Google Scholar
• CARMELIET P, KIECKENS L, SCHOONJANS L et al.: Plasminogen activator inhibitor-I gene-deficient mice. I. Generation by homologous recombination and characterization. j Clirr. Invest. (1993) 92(6):2746–55.
   Google Scholar
• CARMELIET P, SCHOONJANS L, KIECKENS L et al.: Physiological consequences of loss of plasminogen activator gene function in mice. Nature (1994) 368(6470):419–424.
   PubMed Web of Science ®Google Scholar
• DEWERCHIN M, NUFFELEN AV, WALLAYS G et al.: Generation and characterization of urokinase receptor-deficient mice. j OM. Invest. (1996) 97(3):870–878.
   PubMed Web of Science ®Google Scholar
• STORZEBECHER J; MARKWARDT F: Synthetische Inhibitoren der Serinproteasen. 17. Mitteilung. Einflul3 von Benzamidinderivaten auf die Aktivität der Urokinase und den Ablauf der Fibrinolyse. Pharmazie (1978) 33:599–602.
   Google Scholar
• SPERL S, JACOB U, ARROYO DE PRADA N et al.: (4-aminomethyfi-phenylguanidine derivatives as non-peptidic highly selective inhibitors of human urokinase. X-ray crystal structure of an uPA/ inhibitor complex at 1.8 A resolution. Proc. Natl. Acad. Sri. USA (2000) 97:5113–5118.
   Google Scholar
• •Unique binding mode of a uPA inhibitor.
   Google Scholar
• NIENABER V, WANG J, DAVIDSON D et al.: Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite. j Biol. Chem. (2000) 275:7239–7248.
   PubMed Web of Science ®Google Scholar
• GERATZ JD, SHAVER SR, TID WELL RR: Inhibitory effect of amidino-substituted heterocyclic compounds on the amidase activity of plasmin and of high and low molecular weight urokinase and on urokinase-induced plasminogen activation. Thromb. Res. (1981) 24:73–83.
   PubMed Web of Science ®Google Scholar
• TIDWELL RR, GERATZ JD, DUBOVI EJ: Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin, and trypsin. I Med. Chemistry (1983) 26:294–298.
   PubMed Web of Science ®Google Scholar
• BILLSTROM A, HARTLEY-ASP B, LECANDER I, BATRA S, ASTEDT B: The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in SCID mice. Int. Cancer (1995) 61:542–547.
   PubMed Web of Science ®Google Scholar
• JANKUN J, KECK RW, SKRZYPCZAK-JANKUN E, SWIERCZ R: Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res. (1997) 57:559–563.
   PubMed Web of Science ®Google Scholar
• VASSALLI JD, BELIN D: Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Letters (1987) 14:187–191.
   Google Scholar
• TOWLE MJ, LEE A, MADUAKOR EC, SCHWARTZ CE, BRIDGES AJ, LITTLEFIELD BA: Inhibition of urokinase by 4-substituted benzolblthiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res. (1993) 53:2553–2559.
   PubMed Web of Science ®Google Scholar
• ALONSO DF, FARIAS EF, LADEDA V, DAVEL L, PURICELLI L, JOFFE EBD: Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Breast Cancer Res. Treat. (1996) 40:209–223.
   PubMed Web of Science ®Google Scholar
• ALONSO DF, TEJERA AM, FARIAS EF, JOFFE EBD, GOMEZ DE: Inhibition of mammary tumor cell adhesion, migration, Expert Op/n. Biol. Ther. (2001) 1(4) and invasion by the selective synthetic urokinase inhibitor B428. Anti-Cancer Res. (1998) 8:4499–4504.
   Google Scholar
• •Inhibition of mammary carcinoma growth by a urokinase inhibitor.
   Google Scholar
• RABBANI SA, HARAKIDAS E DAVIDSON DJ, HENKIN J, MAZAR AP: Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPP). Int.j Cancer (1995) 63:840–845.
   PubMed Web of Science ®Google Scholar
• XING RH, MAZAR A, HENKIN J, RABBANI SA: Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res. (1997) 57:3585–3593.
   PubMed Web of Science ®Google Scholar
• SWIERCZ R, SKRZYPCZAK-JANKUN E, MERRELL MM, SELMAN SH, JANKUN J: Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator. Oncol. Rep. (1999) 6:523–526.
   PubMed Web of Science ®Google Scholar
• TAMURA SY, WEINHOUSE MI, ROBERTS CA et al.: Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors. Bioorg. Med. Chem. Lett. (2000) 10:983–987.
   PubMed Web of Science ®Google Scholar
• STORZEBECHER J, PRASA D, HAUPTMANN J, VIEWEG H, WILKSTROM P: Synthesis and structure-activity relationships of potent thrombin inhibitors - piperazides of 3-amidinophenylalanine. j. Med. Chem. (1997) 40:3091–3099.
   PubMed Web of Science ®Google Scholar
• STORZEBECHER J, VIEWEG H, STEINMETZER T et al.: 3-amidinophenylalanine-based inhibitors of urokinase. Bioorg. Med. Chem. Lett. (1999) 9:3147–3152.
   PubMed Web of Science ®Google Scholar
• ZESLAWSKA E, SCHWEINITZ A, KARCHER A et al.: Crystals of the urokinase type plasminogen activator variant Pc-uPA in complex with small molecule inhibitors open the way towards structure based drug design. j. Mol. Biol. (2000) 301:465–475.
   PubMed Web of Science ®Google Scholar
• ••uPA crystal structure.
   Google Scholar
• NIENABER VL, DAVIDSON D, EDALJI R et al.: Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite. Structure Folding Design (2000) 8:553–563.
   Google Scholar
• •Potent inhibitors with new binding mode.
   Google Scholar
• NIENABER VL, RICHARDSON PL, KLIGHOFER V, BOUSKA JJ, GIRANDA VL, GREER J: Discovering novel ligands for macromolecules using x-ray crystallographic screening. Nature Biotech. (2000) 18:1105–1108.
   PubMed Web of Science ®Google Scholar
• APPELLA E, BLASI F: The growth factormodule of urokinase is the binding sequence for its receptor. Ann. NY Arad Li. (1987) 511:192–195.
   PubMed Web of Science ®Google Scholar
• APPELLA E, ROBINSON EA, ULLRICH SJ et al.: The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. I Biol. Chem. (1987) 262:4437–4440.
   PubMed Web of Science ®Google Scholar
• MAGDOLEN V, RETTENBERGER P, KOPPITZ M et al.: Systematic mutationalanalysis of the receptor-binding region of the human urokinase-type plasminogen activator. Eur. j Biochem. (1996) 237:743–751.
   PubMedGoogle Scholar
• BURGLE M, KOPPITZ M, RIEMER C et al.: Inhibition of the interaction of urokinase-type plasminogen activator (uPP) with its receptor (uPAR) by synthetic peptides. Biol. Chem. (1997) 378:231–237.
   PubMed Web of Science ®Google Scholar
• GOODSON RJ, DOYLE MV, KAUFMAN SE, ROSENBERG S: High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Natl. Acad. Sci. (1994) 91:7129–7133.
   PubMed Web of Science ®Google Scholar
• LUTHER T, MAGDOLEN V, ALBRECHT S et al.: Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am. J. PathoL (1997) 150(4):1231–1244.
   PubMed Web of Science ®Google Scholar
• LI H, LU H, GRISCELLI F etal.: Adenovirus-mediated delivery of a uPA/ uPA-R antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther. (1998) 5:1105–1113.
   Google Scholar
• LI H, GRISCELLI F, LINDENMEYER F etal.: Systemic delivery of antiangiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice. Hum. Gene Ther. (1999) 10:3045–3053.
   Google Scholar
• MOHAN PM, CHINTALA SK, MOHANAM S et al.: Increased invasion of neuroglioma cells transfected with urokinase plasminogen activator receptor cDNA. Cancer Res. (1999) 59:3369–3373.
   PubMed Web of Science ®Google Scholar
• MAD, GERARD RD, LI XY, ALIZADEH H, NIEDERKORN JY: Inhibition of metastasis of intraocular melanomas by adenovirus- mediated gene transfer of plasminogen activator inhibitor Type 1 (PAI- 1) in an athymic mouse model. Blood (1997) 90:2738–2746.
   PubMed Web of Science ®Google Scholar
• PRAUS M, WAUTERICKX K, COLLEN D, GERARD RD: Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors. Gene Ther. (1999) 6:227–236.
   PubMed Web of Science ®Google Scholar
• BRAND K, BAKER AH, PEREZ-CANTOA et aL.: Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res. (2000) 60:5723–5730.
   Google Scholar
• KOBAYASHI H, SUGINO D, SHE MY et al.: A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis. Eur. Biochem. (1998) 253:817–826.
   PubMedGoogle Scholar
• •Bifunctional inhibitor of serine proteases and uPA/uPA-R interaction.
   Google Scholar
• MUEHLENWEG B, ASSFALG-MACHLEIDT I, PARRADO SG et al.: A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ ligand interaction. Cystatin with a urokinase receptor binding site. j. Biol. Chem. (2000) 275:33562–33566.
   Google Scholar
• •First report of a bifunctional inhibitor interfering with different proteolytic systems.
   Google Scholar
• KOBAYASHI H, SCHMITT M, GORETZKI L et al.: Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). j Biol. Chem. (1991) 266:5147–5152.
   PubMed Web of Science ®Google Scholar
• ROSENBERG S: Modulators of the urokinase-type plasminogen activation system for cancer. Expert Opin. Ther. Patents (2000) 10:1843-1852. Review on uPA-related patents.
   Google Scholar
• MISHIMA K, MAZAR AP, GOWN A et al.: A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angigogenesis in vivo in combination with cisplatin. PNAS (2000) 97:8484–8489.
   PubMed Web of Science ®Google Scholar
• SWIERCZ R, KECK RW, SKRZYPCZAK-JANKUN E, SELMAN SH, JANKUN J: Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. OricoL Rep. (2001) 8:463–470.
   Google Scholar
• BASELGA J: Clinical trials of Herceptin® (trastuzumab). Eur j Cancer (2001) 37\(Suppl. 1):18–24.
   Google Scholar
• ••Combination therapy of a specific biologicaltherapeutic with conventional chemotherapy.
   Google Scholar
• W09906393 (1999).
   Google Scholar
• HOFFMANN-LA ROCHE AG: W09906387 (1999).
   Google Scholar
• WILEX BIOTECHNOLOGY GMBH: W00062071 (2000).
   Google Scholar